The startup has developed a genetic engineering platform that enables long-chain DNA synthesis for the production of microbes and combinatorial DNA libraries. This technology addresses the limitations of traditional DNA synthesis methods, facilitating more efficient and scalable genetic engineering applications for medical professionals.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional DNA synthesis methods face limitations in efficiently producing long-chain DNA sequences and complex combinatorial DNA libraries, hindering advancements in synthetic biology and genetic engineering. This inefficiency increases the time and cost associated with developing novel biological tools and therapeutics.
Solution
Synplogen provides a genetic engineering platform that overcomes these limitations through its proprietary OGAB® (Ordered Gene Assembly in _Bacillus subtilis_) method and Combinatorial-OGAB™ technology. OGAB® enables the synthesis of long-chain DNA, ranging from a few kb to over 100 kb, with high accuracy, even for sequences with high GC or AT content or repetitive elements. Combinatorial-OGAB™ facilitates the creation of large, diverse DNA libraries, accelerating the discovery and optimization of gene clusters for various applications. Synplogen also offers Gene Therapy Biofoundry™ services, providing comprehensive solutions for the design, development, and analysis of gene therapy products, including viral vectors, leveraging its DNA synthesis capabilities and GMP-compliant manufacturing partnerships.
Target Audience
Synplogen serves pharmaceutical companies, biotech startups, and research institutions involved in synthetic biology, gene therapy, and biomanufacturing.
Features
- OGAB® technology for synthesizing long and complex DNA sequences with high fidelity
- Combinatorial-OGAB™ for generating diverse DNA libraries tailored to specific client needs
- All-in-One Plasmid™ technology to streamline AAV vector production by incorporating all necessary genes into a single plasmid
- Capability to synthesize DNA sequences that are difficult or impossible to clone in _E. coli_
- Gene Therapy Biofoundry™ services for sequence design, process development, analytical development, and quality control of gene therapy products
- GMP-compliant manufacturing partnerships to ensure a seamless transition from development to clinical trials
- Expertise in viral vector design and production, including AAV and lentivirus vectors
- Capabilities for mRNA design and production
- Ultra-centrifugation plasmid purification